 Cyclophosphamide cisplatin versus cyclophosphamide doxorubicin cisplatin chemotherapy ovarian carcinoma meta-analysis Ovarian Cancer Meta-Analysis Project randomized clinical trials cyclophosphamide cisplatin CP versus cyclophosphamide doxorubicin cisplatin CAP significant survival difference treatment ovarian carcinoma patients trials meta-analysis significant survival benefit CAP addition significant advantage CAP frequency negative second-look laparotomy CAP CP dose intensity CAP CP trials unresolved benefit CAP dose intensity extent doxorubicin interpretation directions chemotherapy ovarian carcinoma